Hormone Therapy and Risk of Breast Cancer: Where Are We Now?

키워드

참고문헌 (36)

1. Siegel RL, "Cancer statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
2. Singletary SE, "Rating the risk factors for breast cancer", Ann Surg, 237, pp.474~482 (2003)
3. Marchetti C, "Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1and BRCA2 mutation carriers : a meta-analysis", Crit Rev Oncol Hematol, 132, pp.111~115 (2018)
4. Silva Filho ALD, "Hormone therapy after risk-reducing surgery in patients with BRCA1", BRCA2 mutation : evaluation of potential benefits and safety, 2020, pp.66, 1134~1138
5. Collaborative Group on Hormonal Factors in Breast Cancer, "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence", Lancet, 394, pp.1159~1168 (2019)
6. Bhavnani BR, "Pharmacology of conjugated equine estrogens : efficacy, safety and mechanism of action", J Steroid Biochem Mol Biol, 142, pp.16~29 (2014)
7. Grady D, "Hormone therapy to prevent disease and prolong life in postmenopausal women", Ann Intern Med, 117, pp.1016~1037 (1992)
8. Anderson GL, "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial", JAMA, 291, pp.1701~1712 (2004)
9. Beral V, "Breast cancer and hormone-replacement therapy in the Million Women Study", Lancet, 362, pp.419~427 (2003)
10. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
11. Althuis MD, "Etiology of hormone receptor-defined breast cancer : a systematic review of the literature", Cancer Epidemiol Biomarkers Prev, 13, pp.1558~1568 (2004)
12. Hilton HN, "Impact of progesterone on stem", progenitor cells in the human breast, 2015, pp.20, 27~37
13. Key TJ, "Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women", J Natl Cancer Inst, 95, pp.1218~1226 (2003)
14. Chlebowski RT, "Abstract GS5-00. Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence:the Women's Health Initiative randomized trials", Cancer Res, 80(4 Suppl) (2020)
15. Manson JE, "Menopausal hormone therapy and long-term all-cause and cause-specific mortality : the Women's Health Initiative randomized trials", JAMA, 318, pp.927~938 (2017)
16. Ness J, "Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial", J Gerontol A Biol Sci Med Sci, 60, pp.460~462 (2005)
17. Ravdin PM, "The decrease in breast-cancer incidence in 2003 in the United States", N Engl J Med, 356, pp.1670~1674 (2007)
18. Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials", JAMA, 310, pp.1353~1368 (2013)
19. The North American Menopause Society, "The 2017 hormone therapy position statement of The North American Menopause Society", Menopause, 24, pp.728~753 (2017)
20. Vinogradova Y, "Use of hormone replacement therapy and risk of breast cancer : nested case-control studies using the QResearch and CPRD databases", BMJ, 371, pp.m3873~ (2020)
21. Albertazzi P, "A review of non-hormonal options for the relief of menopausal symptoms", Treat Endocrinol, 5, pp.101~113 (2006)
22. Imai A, "New generation nonhormonal management for hot flashes", Gynecol Endocrinol, 29, pp.63~66 (2013)
23. Loprinzi CL, "Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors", J Clin Oncol, 16, pp.2377~2381 (1998)
24. Handley AP, "The efficacy and tolerability of SSRI", SNRIs in the treatment of vasomotor symptoms in menopausal women : a systematic review, 2015, pp.27, 54~61
25. Loprinzi L, "Pilot evaluation of gabapentin for treating hot flashes", Mayo Clin Proc, 77, pp.1159~1163 (2002)
26. Franco OH, "Use of plant-based therapies and menopausal symptoms : a systematic review and meta-analysis", JAMA, 315, pp.2554~2563 (2016)
27. Shams T, "Efficacy of black cohosh-containing preparations on menopausal symptoms : a meta-analysis", Altern Ther Health Med, 16, pp.36~44 (2010)
28. Goldberg RM, "Transdermal clonidine for ameliorating tamoxifen-induced hot flashes", J Clin Oncol, 12, pp.155~158 (1994)
29. Loprinzi CL, "Phase III evaluation of fluoxetine for treatment of hot flashes", J Clin Oncol, 20, pp.1578~1583 (2002)
30. Carroll DG, "Critical appraisal of paroxetine for the treatment of vasomotor symptoms", Int J Womens Health, 7, pp.615~624 (2015)
31. Burke GL, "Soy protein and isoflavone effects on vasomotor symptoms in peri-and postmenopausal women : the Soy Estrogen Alternative Study", Menopause, 10, pp.147~153 (2003)
32. Loibl S, "Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study", Ann Oncol, 18, pp.689~693 (2007)
33. Guttuso T Jr, "Gabapentin's effects on hot flashes in postmenopausal women : a randomized controlled trial", Obstet Gynecol, 101, pp.337~345 (2003)
34. Avis NE, "Duration of menopausal vasomotor symptoms over the menopause transition", JAMA Intern Med, 175, pp.531~539 (2015)
35. Goldstein I, "Recognizing and treating urogenital atrophy in postmenopausal women", J Womens Health(Larchmt), 19, pp.425~432 (2010)
36. Sarrel P, "Incremental direct and indirect costs of untreated vasomotor symptoms", Menopause, 22, pp.260~266 (2015)

관련 논문AI추천